secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-038865
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Q4 2023: FDA approves IDE for Revita weight-maintenance study; gene therapy candidate RJVA-001 nominated
--------------------------------------------------------------------------------

- FDA IDE approval for Revita Remain-1 pivotal study for weight maintenance in obesity patients after GLP-1 discontinuation; enrollment expected H2 2024.
- Enrollment in Revitalize-1 T2D pivotal study expected to complete Q2 2024; topline data Q4 2024.
- Announced RJVA-001 as first GLP-1 pancreatic gene therapy candidate; IND-enabling studies to complete H2 2024.
- Completed IPO raising ~$100.3M net; cash on hand expected to fund operations through 2025.
- FY 2023 net loss $77.1M vs $46.5M in 2022; revenue insignificant $0.1M; R&D expense $38.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024038865/0000950170-24-038865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024038865/guts-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer